Zoetis Inc. $ZTS Shares Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 537.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,650 shares of the company’s stock after purchasing an additional 9,822 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Zoetis were worth $1,817,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Howe & Rusling Inc. boosted its stake in Zoetis by 9.4% during the second quarter. Howe & Rusling Inc. now owns 2,382 shares of the company’s stock worth $371,000 after buying an additional 205 shares during the period. Quilter Plc lifted its holdings in shares of Zoetis by 6.0% in the 2nd quarter. Quilter Plc now owns 398,344 shares of the company’s stock worth $62,122,000 after acquiring an additional 22,516 shares during the last quarter. Artisan Partners Limited Partnership purchased a new position in shares of Zoetis during the 2nd quarter worth approximately $115,918,000. Empirical Finance LLC increased its holdings in Zoetis by 0.6% in the 2nd quarter. Empirical Finance LLC now owns 16,090 shares of the company’s stock valued at $2,509,000 after purchasing an additional 98 shares during the last quarter. Finally, TD Waterhouse Canada Inc. raised its position in Zoetis by 4.5% in the second quarter. TD Waterhouse Canada Inc. now owns 16,946 shares of the company’s stock valued at $2,697,000 after purchasing an additional 734 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 1.0%

Shares of NYSE ZTS opened at $116.96 on Thursday. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $181.85. The stock has a market capitalization of $51.54 billion, a price-to-earnings ratio of 20.13, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The firm has a 50-day moving average price of $138.98 and a 200 day moving average price of $150.66. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Analyst Ratings Changes

ZTS has been the topic of several research reports. JPMorgan Chase & Co. cut their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research cut their price target on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. UBS Group reduced their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.